Yanchun Jia

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Wanting Qiang, Jing Lü et al. · Blood · 2023 · 20 citations

B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma

Wanting Qiang, Jing Lu, Yanchun Jia et al. · JAMA Oncology · 2024 · 18 citations · Full text